Gentamicin Sulfate Cream 0.1%

GENTAMICIN SULFATE CREAM 0.1%- gentamicin sulfate cream
Sola Pharmaceuticals

DESCRIPTION

Gentamicin Sulfate Cream is a wide spectrum antibiotic preparation for topical administration. Each gram contains Gentamicin Sulfate USP equivalent to 1 mg gentamicin base in a cream base containing stearic acid, propylene glycol monostearate, isopropyl myristate, polysorbate 40, propylene glycol, sorbitol solution and purified water with methylparaben and butylparaben as preservatives.

CLINICAL PHARMACOLOGY

Gentamicin Sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Cream may clear infections that have not responded to treatment with other topical antibiotic agents. In primary skin infections such as impetigo contagiosa, treatment 3 or 4 times daily with Gentamicin Sulfate Cream usually clears the lesions promptly. In secondary skin infections, Gentamicin Sulfate Cream aids in the treatment of the underlying dermatoses

by controlling the infection. Bacteria susceptible to the action of gentamicin sulfate include sensitive strains of Streptococci (group A beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative, and some penicillinase-producing strains), and the gram-negative bacteria, Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae

INDICATIONS AND USAGE

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral

infections. Please Note: Gentamicin Sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin Sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the

treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with Gentamicin Sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical

antibiotic. Gentamicin Sulfate Cream is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. If a water-washable preparation is desired, the cream is preferable. Gentamicin Sulfate Cream has been used successfully in infants over one year of age, as well as in adults and children.

CONTRAINDICATIONS

This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

PERCAUTIONS

The use of topical antibiotics occasionally allows overgrowth of nonsusceptible organisms, including fungi. If this condition occurs, or if irritation, sensitization or superinfection develops, treatment with gentamicin sulfate should be discontinued and appropriate therapy instituted.

ADVERSE REACTIONS

In patients with dermatoses treated with Gentamicin Sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with Gentamicin Sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of Gentamicin Sulfate followed by exposure to ultraviolet radiation.

To report SUSPECTED ADVERSE REACTIONS , contact Teligent Pharma, Inc. at 1-856-697-1441, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

A small amount of Gentamicin Sulfate Cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to treatment with gentamicin sulfate under gelatin packing.

HOW SUPPLIED

Gentamicin Sulfate Cream USP, 0.1% is supplied as follows:

30 gram tube (NDC 70512-036-30)

Store at controlled room temperature 15°-30°C (59°-86°F).

Manufactured for:

SOLA Pharmaceuticals

Baton Rouge, LA 70810

C101322

PI-036-00

Rev 12/2019

Rev. 2

PACKAGE LABEL PRINCIPAL DISPLAY PANEL

NDC 70512-036-30

Gentamicin Sulfate

Cream USP, 0.1%

For Dermatological Use Only

Not for Ophthalmic Use

Keep this and all drugs out of the reach of children.

30 grams

Rx only

Sola Pharmaceuticals

Gentamicin Tube Display
(click image for full-size original)
Gentamicin Carton Display
(click image for full-size original)

GENTAMICIN SULFATE CREAM 0.1%
gentamicin sulfate cream 0.1% cream
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70512-036
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
GENTAMICIN SULFATE (GENTAMICIN) GENTAMICIN 1 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
METHYLPARABEN
BUTYLPARABEN
STEARIC ACID
PROPYLENE GLYCOL MONOPALMITOSTEARATE
POLYSORBATE 40
ISOPROPYL MYRISTATE
PROPYLENE GLYCOL
WATER
SORBITOL
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:70512-036-30 1 TUBE in 1 CARTON contains a TUBE
1 30 g in 1 TUBE This package is contained within the CARTON (70512-036-30)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA209304 04/07/2020
Labeler — Sola Pharmaceuticals (080121345)

Revised: 04/2020 Sola Pharmaceuticals

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.